@ModestDominik
 Berlin, Germany
Joined April 2021
  • Tweets36
  • Following61
  • Followers162
1Media
Health-related quality of life in patients with KRASG12C-mutated chemo... sciencedirect.com/science/ar…
1
2
260
🚨 #LowerGIcancer highlights from #ASCO24 🚨 Prof. @JenSeligmann & Dr @ModestDominik share their views on new data from #COLLISION & #TRANSMET trials presented at the congress. ⬇️🎥⬇️ #MedEd #ASCOhighlights #CRCSM #LowerGI
8
2
27
539,592
🚨#LowerGIcancer highlights from #ASCO24🚨 Medical oncologists Prof. @JenSeligmann and Dr @ModestDominik share their views on new data in #rectalcancer and #CRC from the NEOPRISM-CRC trial & LBA3512. Watch the video 📺 👇 #MedEd #oncology #CRCSM
1
13
1
40
535,092
Dominik Paul Modest retweeted
Myriam Chalabi@MyriamChalabi29 May 2024
Voting open for @myESMO #president 2027-2028! Vote now, or on your way to #ASCO24! My vote 👇 @Prof_Nadia_H #mentor #strong #womenleaders #femalepresident
16
2
30
9,418
Dominik Paul Modest retweeted
NEJM
@NEJM23 Oct 2023
Original Article: Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C (CodeBreaK 300 phase 3 trial) nej.md/3M8Qw3k #ESMO23 #oncology
Progression-free Survival as Assessed by Blinded Independent Central Review (Intention-to-Treat Population)

ALT Progression-free Survival as Assessed by Blinded Independent Central Review (Intention-to-Treat Population)

1
36
2
102
45,863
Five @giconnectInfo experts provide a handy update from #ESMO2022! ➡️ Podcast Ep. 1: Lower #GIcancer highlights ➡️ Podcast Ep. 2: Upper #GIcancer highlights ➡️ Video summary of NICHE-2 trial For the podcasts, video and downloadable content, follow: ow.ly/6GQF50L2EhI #MedEd

GI CONNECT Update from ESMO 2022 | COR2ED

Podcast episode 1: lower GI cancer Dr Jenny Seligmann and Dr Dominik Modest discuss key abstracts on lower GI cancer from ESMO 2022 in Episode 1 of this

cor2ed.com
3
1
7
Dominik Paul Modest retweeted
Jenny Seligmann@JenSeligmann11 Sep 2022
💥💥💥💥@MyriamChalabi #ESMO22 discussing NICHE2 - neoadjuvant nivo/ipi in locally advanced colon cancer 💥short duration safe pre-op 💥4% grade 3 events 💥100% R0 resection 💥95% major path; 67% pCR …round of applause in session! 1/2 – at Paris, France
5
51
8
143
Dominik Paul Modest retweeted
Ben Westphalen@BenWestphalen7 Jun 2022
Well said @FilippoPietran4 …and @myESMO #ESMO22 is approaching fast!
Filippo Pietrantonio@FilippoPietran47 Jun 2022
Late check-out and ready to fly back home🇮🇹! This has been an incredible ASCO for science, meeting new and old friends, discussing projects and also..so much laughing ! @ChiaraCrem1 @lonardi_sara @MyriamChalabi @BenWestphalen @JenSeligmann @ModestDominik @darioT_ @PTarantinoMD
1
2
Dominik Paul Modest retweeted
Kathrin Heinrich@heinrich_kat4 Jun 2022
Proud to present our subgroup analysis of the PANAMA-study according to #gender and age in patients with #colorectalcancer at #ASCO2022! Thanks to my amazing mentors @ModestDominik and @StintzingS for their support!
6
21
Dominik Paul Modest retweeted
Nathanael Raschzok@nathanaelraschz5 Apr 2022
The protocol of the PORT trial is published, which aims to generate evidence that post-resection/ablation/radiation chemotherapy improves the survival in patients with metastatic colorectal cancer. bmccancer.biomedcentral.com/… @ModestDominik @Sauer_et_al

FIRE-9 – PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to...

BMC Cancer - Additive/adjuvant chemotherapy as concept after local treatment of colorectal metastases has not been proven to be successful by phase III trials. Accordingly, a standard of care to...

link.springer.com
1
5
8
Our new podcast series is out! In Episode 2 @JenSeligmann, @McreeAutumn and @ModestDominik are discussing #immunotherapy approaches! Listen to the podcast and download the transcript at: ow.ly/erC950GKbN6 #MedEd #GI #GC
1
1
Eine interdisziplinäre klinische Studie zur Therapie von #Darmkrebs startet nun unter Leitung der #CharitéBerlin. Die FIRE-9/PORT-Studie soll helfen, die Neuentstehung von Metastasen zu verhindern. @ModestDominik @StintzingS @AIO_Onkologie @LMU_Uniklinikum charite.de/service/pressemit…

Pressemitteilung-Detail: Charité – Universitätsmedizin Berlin

Pressemitteilungen der Charité – Universitätsmedizin Berlin

charite.de
1
6
13
Dominik Paul Modest retweeted
CancerNetwork®
@CancerNetwrk10 Jun 2021
Adding panitumumab to 5-FU and leucovorin significantly improved PFS compared with 5-FU/leucovorin alone as a maintenance therapy for patients with RAS wild-type metastatic CRC. #ASCO21 | @ModestDominik cancernetwork.com/view/maint…
1
Dominik Paul Modest retweeted
Sebastian Stintzing@StintzingS7 Jun 2021
Replying to @manjuggm @OncoAlert
You guessed it... having an opinion is not knowing it. 😉
1
2
4
Dominik Paul Modest retweeted
Sebastian Stintzing@StintzingS13 Nov 2020
Good job @ArndtStahler !
This Post is from an account that no longer exists. Learn more
2
4
Dominik Paul Modest retweeted
VJ Oncology
@VJOncology7 Jun 2021
We spoke w/ @StintzingS of @ChariteBerlin on findings of the Phase II FIRE-4.5 Watch here ➡️ow.ly/YBSM50F4Q5Y @VJOncology @ASCO #ASCO21 @OncoAlert #ColorectalCancer #CRCsm #CRC #GIsm

FIRE-4.5: FOLFOXIRI plus either bevacizumab or cetuximab in mCRC

Sebastian Stintzing, MD, Charité Universitätsmedizin Berlin, Berlin, Germany, describes the findings of the Phase II FIRE-4.5 study (NCT04034459) of FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin,...

vjoncology.com
5
4
Dominik Paul Modest retweeted
Dr. Cathy Eng
@CathyEngMD7 Jun 2021
On behalf of myself and @GIcancerDoc, we would like to 🙏our amazing #colorectal #cancer #asco21 track leader, @AndreaCercek for organizing these abstracts for our session! And thank YOU to ALL the participants that sent in GREAT questions!! 💙 #CancerResearch #clinicaltrials
3
5
54
Dominik Paul Modest retweeted
Dr Joseph McCollom DO
@realbowtiedoc7 Jun 2021
Replying to @ModestDominik
@ModestDominik shows the study schema for the PANAMA-AIO KRK 0212 investigating maintenance in RAS WT patients after induction with 5FU/LV + Pani vs 5FU/LV alone. #crcsm #GIonc #ASCO21
2
1
Dominik Paul Modest retweeted
OncLive.com
@OncLive7 Jun 2021
Cetuximab Did Not Improve ORR Compared with Bevacizumab for RAS wild type BRAF V600E mutant mCRC @StintzingS @ChariteBerlin @ASCO #ASCO21 #crcsm ow.ly/q2Gv50F4Zf8

Cetuximab Misses ORR End Point in RAS Wild-Type, BRAF V600E+ mCRC | OncLive

The chemotherapy regimen of FOLFOXIRI plus bevacizumab was found to be preferred in terms of antitumor activity compared with FOLFOXIRI plus cetuximab in patients with RAS wild-type, BRAF V600E–mut...

onclive.com
6
10
Dominik Paul Modest retweeted
Dr Joseph McCollom DO
@realbowtiedoc7 Jun 2021
Replying to @ModestDominik
@ModestDominik presents primary outcome of the PANAMA trial showing improved PFS in 5FU/LV+pani maintenance 8.8 mo vs 5FU/LV alone 5.7 mo. OS data is yet immature #crcsm #GIonc #ASCO21
3
1
Load more